Peer-reviewed findings with our proprietary technology: Evoked Potential Tomography (EPT). Ceregram runs on EPT, which is evidenced in clinical publications for Alzheimer’s, Schizophrenia, and other indications. EPT has several research names, including CASBA and JH-FLKR.
Clinical research shows strong correlations between Ceregram metrics and established biomarkers. These research findings support the use of Ceregram for monitoring and clinical context — not as a standalone diagnostic tool.
Summary of Key Findings
| Measure | Correlation (r) | RMSE | Result |
|---|---|---|---|
| Amyloid-PET SUVR | 0.89 | 6% | Excellent |
| p-Tau181 (pg/mL) | 0.92 | 5% | Excellent |
| Cognitive Score: FCSRT | 0.94 | 4% | Excellent |
| Cognitive Score: MMSE | 0.84 | 8% | Excellent |
| Cognitive Score: CERAD | 0.78 | 10% | Very Strong |
| Disease Differentiation (Alzheimer's vs. Lewy Body vs. Healthy & other stages) |
0.95 | N/A | Excellent |
p-values < 0.01
Posters
AAN 2026: Alzheimer’s unified biomarker
ADPD 2026: PET vs EEG amyloid imaging
AAN 2025: correlating all endpoints
AAIC 2023: Alzheimer’s early classifier
Publications
NEW Estimation of positron emission tomography amyloid load and related biomarkers in Alzheimer’s disease using evoked potential tomography EEG: development and internal validation in a cross-sectional cohort
Direct evaluation of Vistim Labs’ EPT method for estimating PET-amyloid SUVR, CSF p-tau181, and cognitive scores in a cross-sectional cohort of participants with AD, MCI, and normal cognition. Models achieved strong correlations with the actual biomarker values. These results support EPT as a portable tool for estimating multiple AD biomarkers in a single session for AD detection and monitoring.
Alzheimer’s Research and Therapy, 12 June 2026
Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment
Amyloid deposition is a key predictor of Alzheimer’s disease (AD) and related neurodegenerative disorders. Changes in the retina’s ganglion cell layer are linked to AD. The study examines EEG visual event-related potentials (vERP) as a measure of dysfunction in visual systems tied to the ganglion cell layer. Specifically, it assesses how amyloid deposition affects vERP in aging and mild cognitive impairment (MCI) populations. The research aims to clarify the connection between amyloid buildup and vERP changes, potentially aiding early AD detection and progression monitoring.
Alzheimer’s Research and Therapy, 28 Februrary 2023
Roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology
Developing treatments for psychiatric disorders relies on physiological measures that bridge the gap between animal models and human studies. Traditional EEG event-related potentials (ERPs) vary significantly across species. Neuro-oscillatory responses, analyzed in the time-frequency domain, offer more consistent comparisons and insights into local circuit mechanisms. This paper outlines a roadmap for using neuro-oscillatory responses as translational biomarkers in the development of neuropsychiatric treatments, improving translation from animal models to clinical studies.
Neuropsychopharmacology, 6 May 2020
Differential patterns of visual sensory alteration underlying face emotion recognition impairment and motion perception deficits in schizophrenia and autism spectrum disorders
Schizophrenia (SZ) and autism spectrum disorder (ASD) share face-emotion recognition and motion processing deficits. SZ shows reduced brain activation and lower EEG power in motion-sensitivity regions, while ASD features dorsal stream hyperactivation and increased theta power. Both groups exhibit abnormal alpha-band modulation in the pulvinar, predicting clinical symptoms. These distinct profiles suggest potential treatments for regulating visual processing in SZ and ASD.
Biological Psychiatry, 1 October 2019
Impaired motion processing in schizophrenia and the attenuated psychosis syndrome: etiological and clinical implications
This study explores motion perception deficits in schizophrenia and clinical high-risk (attenuated psychosis) patients, revealing impairments linked to face-emotion recognition and cognitive function. Unlike motion, sensory responses are preserved in attenuated psychosis. In schizophrenia, motion deficits are associated with impaired motion-sensitive visual cortex activity. These findings use EEG to underscore sensory-level visual dysfunction’s role in schizophrenia, potentially preceding illness onset and affecting clinical high-risk patients.
American Journal of Psychiatry, 3 October 2018